| Code | CSB-RA016091MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to vesencumab, targeting Neuropilin-1 (NRP1), a transmembrane glycoprotein that functions as a co-receptor for multiple signaling pathways. NRP1 plays critical roles in angiogenesis, neuronal guidance, and immune regulation by binding to class 3 semaphorins and various members of the vascular endothelial growth factor (VEGF) family. Aberrant NRP1 expression has been implicated in tumor progression, metastasis, and resistance to anti-angiogenic therapies across multiple cancer types, including pancreatic, colorectal, and lung cancers. Additionally, NRP1 contributes to immune evasion by modulating T cell function and promoting immunosuppressive tumor microenvironments.
Vesencumab was originally developed as a therapeutic antibody designed to block NRP1-mediated VEGF signaling, thereby inhibiting pathological angiogenesis and tumor growth. This biosimilar provides researchers with a valuable tool for investigating NRP1's multifaceted roles in cancer biology, vascular development, neural patterning, and immune modulation. It enables studies exploring NRP1 as a potential therapeutic target and its involvement in treatment resistance mechanisms.
There are currently no reviews for this product.